読み込み中
NASDAQHealthcareBiotechnology
最新データ
$4.76
+$0.05 · +1.06%
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
前日終値
$4.76
+$0.05 · +1.06%
日中の時刻はETです。市場データは遅延する場合があります。
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
日中レンジ
現在 $4.76
52週レンジ
現在 $4.76
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
31
割高
センチメント
41
まちまち
リスク
93
極めて高いリスク
モメンタム
54
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
日中レンジ
現在 $4.76
52週レンジ
現在 $4.76
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 研究開発 | 4893.6万 USD | 1736.3万 USD | 448万 USD | 717.2万 USD |
| 販売・一般管理 | 1378.9万 USD | 530.5万 USD | 217.3万 USD | 270.2万 USD |
| 営業費用 | 6272.5万 USD | 2278.5万 USD | 741.5万 USD | 1136.3万 USD |
| 受取利息 | 513.9万 USD | 241.4万 USD | 142.3万 USD | 12万 USD |
| 減価償却費と償却費 | 3.6万 USD | 1.6万 USD | 9.7万 USD | 11万 USD |
| 営業利益 | −6272.5万 USD | −2278.5万 USD | −741.5万 USD | −1136.3万 USD |
| 純利益 | −5759.1万 USD | −2058.8万 USD | −720.8万 USD | −1356.4万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI249.29万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF85.64万0.00%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB46.05万0.00%108.2億 USD0.44%$206.49+3.00%
iShares Micro-Cap ETFIWC18.87万0.01%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11万0.10%1.17億 USD0.73%$15.9402+0.25%
Avantis U.S. Small Cap Equity ETFAVSC2.19万—30.82億 USD0.25%$69.98+0.03%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.06万0.00%61.81億 USD0.26%$68.28+0.25%
Invesco Nasdaq Biotechnology ETFIBBQ7639.80.01%1.12億 USD0.19%$34.62+2.96%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVInvesco Nasdaq Biotechnology ETFIBBQAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
